Biography for Carly Helfand
Carly Helfand, News Editor
Carly Helfand is a news editor with Fierce's life sciences group, writing for FiercePharma, FiercePharmaMarketing and FierceVaccines. Carly got her start covering pharma while earning her master’s at Northwestern University’s Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post’s “Wonkblog” and Cape Town’s Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at email@example.com and follow her on Twitter at @CarlyHFierce.
- Contact Carly
- Follow Carly on Google+
Articles by Carly Helfand
What's the value of Novartis' meningitis B vaccine, Bexsero, to the U.K.? It's a question the company and the country's government have been debating for months now, unable to come to terms on a reasonable price for the jab. But medical journal The BMJ might have an answer.
India's rotavirus vaccines market is headed for a shake-up, and Sanofi's angling to get in on the action. It got one step closer this week, with its Indian affiliate commencing Phase III clinical trials for its own investigational vaccine.
As it works to refine its vaccine strategy for the event of an avian flu pandemic, the NIH is trialing Sanofi's H7N9 vaccine at a range of doses and with a variety of adjuvant combinations. And now, it has one that looks promising.
When Australian biotech Admedus announced Phase I results for its herpes simplex virus vaccine last week, it was far from the first company to do so. A whole new generation of vaccinemakers are trying their hand in a race that's heating up.
There's change at the top of a couple of vaccinemakers, with a pair of companies this week announcing upcoming roster moves. For Takeda, that means signing on a new head of vaccine development, while Novartis' vaccine division head will hit the road.
The weightless microgravity environment of space can alter disease-causing bacteria as they grow--and that's not necessarily a bad thing.
When John Vansteenkiste of Belgium University Hospitals Leuven reported the full results of GlaxoSmithKline's MAGE-A3 failure at the European Society of Medical Oncology's annual congress last weekend, he wasn't the first to outline a cancer vaccine flop. But he did offer a way out from under the dark cloud hanging over the field, and it's one that some cancer vaccine makers are already embracing.
According to the World Health Organization, an incorrect diluent for the measles/rubella vaccine most likely caused the recent deaths of 15 Syrian children in rural Idleb.
As GlaxoSmithKline's flu vaccine manufacturing struggles in Canada continue, Sanofi is moving into the country with its own four-strain flu blocker. Its Fluzone Quadrivalent will roll out in Canada starting this flu season, it said Wednesday.
Merck's investigational, 9-valent HPV vaccine has the potential to block about 90% of invasive cervical cancer cases worldwide, new research shows. But getting there will be no walk in the park. First, the company will have to solve some uptake problems that have been plaguing the candidate's predecessor, Gardasil, since it rolled out in 2006.